, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 2. Costs of sales and gross profit Costs of sales were Baht 117 .60 million in the first nine months of 2019, a surge of Baht 32 .42 million
net loss includes unrealized loss on foreign exchange of 19.29 million baht. Comparing with last year, the Company had a net loss of 64.72 million baht which includes unrealized gain on foreign exchange
had a net loss of 34.71 million baht in which there is a loss attributable for the equity holders of the Company of 34.72 million baht and the net loss includes an unrealized gain on foreign exchange of
result Million Baht 2019 2018 Sales 1,748.29 1,905.09 Cost of Sales 1,636.11 1,756.98 Gross Margin 112.17 148.11 Gain (loss) on exchange rates 38.44 (26.43) Other Incomes 33.76 30.28 Total Revenues
result Million Baht 2018 2017 Sales 1,905.09 1,849.88 Cost of Sales 1,756.98 1,621.03 Gross Margin 148.11 228.85 Gain (loss) on exchange rates (26.43) 23.44 Other Incomes 30.28 27.42 Total Revenues
continuous improvement in consumer confidence and household income. Private investment expanded in line with private consumption and capital outlays arising from production relocation to Thailand of some
foreign exchange of 11.97 million baht. If excluding the unrealized gain (loss) on foreign exchange, the Company had a net loss of 68.75 million baht this year and 86.28 million baht last year. The net loss
a loss attributable for the equity holders of the Company of 48.58 million baht and the net loss includes unrealized gain on foreign exchange of 0.49 million baht. Comparing with last year, the
Baht 26.44 million from mutual fund and private fund managements fee from Solaris Asset Management Company Limited (Solaris) decreased. Gain and return on financial instruments decreased of Baht 22.50